A series of new 2-methoxy-4-(5-phenyl-4,5-dihydro-1H-pyrazol-3-yl)phenolderivatives, 4–13, were synthesized and tested for their human MAO inhibitory
activity.
All the compounds were found to be selective and reversible toward
hMAO-A except 4, a selective inhibitor of hMAO-B and 12, a nonselective inhibitor. Compound 7 was
found to be a potent inhibitor of hMAO-A with Ki = 0.06 ± 0.003 μM and was having selectivity
index of (SI = 1.02 × 10–5). It was found to
be better than standard drug, Moclobemide (hMAO-A with Ki = 0.11 ± 0.01 μM) with selectivity index
of SI = 0.049. Molecular docking simulation was carried out to understand
the crucial interactions responsible for selectivity and potency.